|
 | Up a level |
Hughes, Diana, Waddingham, Ed, A., J., Mt-Isa, Shahrul, Goginsky, Alesia, Chan, Edmond, Downey, Gerald, Hallgreen, Christine E., Hockley, Kimberley S., Juhaeri, Juhaeri, Lieftucht, Alfons, Metcalfe, Marilyn, A., Noel, Rebecca, A., Phillips, Lawrence D., Ashby, Deborah and Micaleff, Alain (2014) IMI-PROTECT benefit-risk grouprecommendations report:recommendations for the methodology andvisualisation techniques to be used in theassessment of benefit and risk of medicines. . PROTECT Consortium, London.
Micaleff, Alain, Callreus, Tornbjorn, Phillips, Lawrence D., Hughes, Diana, Hockley, Kimberley, Wang, Nan and Luciani, David (2013) IMI work package 5: report 1:b:iii benefit - riskwave 1 case study report:Raptiva® (efalizumab). . PROTECT Consortium, London.
Phillips, Lawrence D., Amzal, Billy, Asiimwe, Alex, Chan, Edmond, Chen, Chen, Hughes, Diana, Juhaeri, Juhaeri, Micaleff, Alain, Mt-Isa, Shahrul, Noel, Becky, Shepherd, Susan and Wang, Nan (2013) IMI work package 5: report 2:b:ii benefit - riskwave 2 case study report: Rosiglitazone. . PROTECT Consortium, London.
Mt-Isa, Shahrul, Hallgreen, Christine, E., Asiimwe, Alex, Downey, Gerry, Genov, Georgy, Hermann, Richard, Hughes, Diana, Lieftucht, Alfons, Noel, Rebecca, Peters, Ruth, Phillips, Lawrence D., Shepherd, Susan, Micaleff, Alain, Ashby, Deborah and Tzoulak, Ioanna (2013) Review of visualisation methods for therepresentation of benefit-risk assessment ofmedication: stage 2 of 2. . PROTECT Consortium, London.
